Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation

Experimental Hematology

Volumn 36, Issue 12, 2008, Pages 1750-1759

  Prigozhina, Tatyana B ^a   Elkin, Gregory ^a   Khitrin, Sofia ^b   Slavin, Shimon ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GRAFT SURVIVAL; IMMUNE RESPONSE; LEUKEMIA; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION CHIMERA; RADIATION DOSE; SINGLE DRUG DOSE; SPLEEN CELL; T LYMPHOCYTE; WHOLE BODY RADIATION;

ACUTE DISEASE; ANIMALS; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; MICE; MICE, INBRED BALB C; MYELOABLATIVE AGONISTS; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; WHOLE-BODY IRRADIATION;

ANIMALIA; MURINAE; MUS;

EID: 55549091691     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2008.07.002     Document Type: Article

References (47)

1. Weiden P.L. Allogeneic bone marrow transplantation. Crit Rev Clin Lab Sci 19 (1983) 173-186
2. Apperley J.F., Jones L., Hale G., et al. Bone marrow transplantation for patients with chronic myeloid leukemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant 1 (1986) 53-66
3. Slavin S., and Kedar E. Current problems and future goals in clinical bone marrow transplantation. Blood Rev 2 (1988) 259-269
4. Cavazzana-Calvo M., Fromont C., Le Deist F., et al. Specific elimination of alloreactive T cells by an anti-Interleukin-2 receptor B-chain-specific immunotoxin. Transplantation 50 (1990) 1-7
5. Solomon S.R., Mielke S., Savani B.N., et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106 (2005) 1123-1129
6. Hartwig U.F., Nonn M., Khan S., Meyer R.G., Huber C., and Herr W. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant 37 (2006) 297-305
7. Wehler T.C., Nonn M., Brandt B., et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood 109 (2007) 365-373
8. Hartwig U.F., Robbers M., Wickenhauser C., and Huber C. Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death. Blood 99 (2002) 3041-3049
9. Chen B.J., Cui X., Liu C., and Chao N.J. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. Blood 99 (2002) 3083-3088
10. Pachnio A., Dietrich S., Klapper W., et al. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation. Bone Marrow Transplant 38 (2006) 157-167
11. Cohen J.L., Boyer O., Salomon B., et al. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 89 (1997) 4636-4645
12. Carella A.M., Champlin R., Slavin S., McSweeney P., and Storb R. Mini-allografts: ongoing trials in humans. Bone Marrow Transplant 25 (2000) 345-350
13. Giralt S., Estey E., Albitar M., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
14. Khouri I.F., Keating M., Korbling M., et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 16 (1998) 2817-2824
15. Slavin S., Nagler A., Naparstek E., et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91 (1998) 756-763
16. Antin J.H., and Ferrara J.L. Cytokine dysregulation and acute graft-versus-host disease. Blood 80 (1992) 2964-2968
17. Teshima T., and Ferrara J.L. Understanding the alloresponse: New approaches to graft-versus-host disease prevention. Semin Hematol 39 (2002) 15-22
18. Gonzalez M., Quezada S.A., Blazar B.R., et al. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning. J Immunol 169 (2002) 5581-5589
19. Prigozhina T.B., Gurevitch O., and Slavin S. Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol 27 (1999) 1503-1510
20. Prigozhina T.B., Elkin G., Khitrin S., and Slavin S. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning. Exp Hematol 32 (2004) 1110-1117
21. Bach J.F. Immunosuppression by chemical agents. Transplant Proc 3 (1971) 27-33
22. Strauss G., Osen W., and Debatin K.M. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 128 (2002) 255-266
23. van Bekkum D.W. Biology of acute and chronic graft-versus-host reactions: predictive value of studies in experimental animals. Bone Marrow Transplant 14 suppl 4 (1994) S51-S55
24. Colson Y.L., Wren S.M., Schuchert M.J., et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers. J Immunol 155 (1995) 4179-4188
25. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14 (2008) 641-650
26. Till J.E., and McCulloch E.A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14 (1961) 213-222
27. Slavin S., and Strober S. Spontaneous murine B-cell leukemia. Nature 272 (1978) 624-626
28. Prigozhina T.B., Gurevitch O., Morecki S., Yakovlev E., Elkin G., and Slavin S. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 30 (2002) 89-96
29. Santos G.W., Sensenbr L.L., Burke P.J., et al. Marrow transplantation in man following cyclophosphamide. Transplant Proc 3 (1971) 400-404
30. Schwartz A., Orbacharbouys S., and Gershon R.K. Participation of cyclophosphamide-sensitive T cells in graft-vs-host reactions. J Immunol 117 (1976) 871-875
31. Mayumi H., Himeno K., Shin T., and Nomoto K. Drug-induced tolerance to allografts in mice. 4. Mechanisms and kinetics of cyclophosphamide-induced tolerance. Transplantation 39 (1985) 209-215
32. Glucksberg H., and Fefer A. Chemotherapy of established graft -versus-host disease in mice. Transplantation 13 (1972) 300-305
33. Eto M., Mayumi H., Tomita Y., Yoshikai Y., Nishimura Y., and Nomoto K. Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion. J Immunol 145 (1990) 1303-1310
34. Eto M., Mayumi H., Tomita Y., et al. Specific destruction of host-reactive mature T-cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol 146 (1991) 1402-1409
35. Mayumi H., Umesue M., and Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 195 (1996) 129-139
36. Mayumi H., and Good R.A. Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide. J Exp Med 169 (1989) 213-238
37. Luznik L., Engstrom L.W., Iannone R., and Fuchs E.J. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 8 (2002) 131-138
38. Colson Y.L., Li H., Boggs S.S., Patrene K.D., Johnson P.C., and Ildstad S.T. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 157 (1996) 2820-2829
39. Luznik L., Jalla S., Engstrom L.W., Iannone R., and Fuchs E.J. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 98 (2001) 3456-3464
40. Luznik L., Fuchs E.J., Chen A.R., et al. Post-transplantation high-dose cyclophosphamide (Cy) is effective single agent GVHD prophylaxis that permits prompt immune reconstitution after myeloablative HLA matched related and unrelated bone marrow transplantation (BMT). Biol Blood Marrow Transplant 13 (2007) 4
41. Tomita Y., Yoshikawa M., Zhang Q.W., et al. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide. J Immunol 165 (2000) 34-41
42. Maury S., Salomon B., Klatzmann D., and Cohen J.L. Division rate and phenotypic differences discriminate alloreactive and nonalloreactive T cells transferred in lethally irradiated mice. Blood 98 (2001) 3156-3158
43. Min B., Yamane H., Hu-Li J., and Paul W.E. Spontaneous and homeostatic proliferation of CD4 T cells are regulated by different mechanisms. J Immunol 174 (2005) 6039-6044
44. Lanzkron S.M., Collector M.I., and Sharkis S.J. Homing of long-term and short-term engrafting cells in vivo. Ann NY Acad Sci 872 (1999) 48-54
45. Marsh J.C. Effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells. Cancer Res 36 (1976) 1853-1882
46. Chertkov J.L., Gelfand I.M., Gurevitch O.A., Lemeneva L.N., and Udalov G.A. Hybrid resistance to parental bone marrow transplantation: adaptive modification of hematopoietic stem cells in a nonsyngeneic environment. Proc Natl Acad Sci U S A 76 (1979) 2955-2959
47. Sefc L., Psenak O., Sykora V., Sulc K., and Necas E. Response of hematopoiesis to cyclophosphamide follows highly specific patterns in bone marrow and spleen. J Hematother Stem Cell Res 12 (2003) 47-61